Literature DB >> 10749290

An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings.

H Mizuno1, H Shibayama, F Tanaka, M Doyu, G Sobue, H Iwata, H Kobayashi, K Yamada, K Iwai, T Takeuchi, N Hashimoto, R Ishihara, Y Ibuki, S Ogasawara, M Ozeki.   

Abstract

An autopsy case with clinically and molecular genetically diagnosed Huntington's disease (HD) accompanied with minimal non-specific neuropathological features was reported. When the patient was 45 years old, he had faulty memory, mood swing, personality change and agitation. Neurological and psychiatric examinations revealed choreoathetoid movements in limbs and trunk, generalized hyperreflexia and mental deterioration. However, cerebellar ataxia and muscle rigidity were not disclosed. Neuroimaging study did not show a definite atrophy of heads of caudate nuclei. Neuroacanthocytosis and Wilson's disease were ruled out by the peripheral blood examination and serum Cu and ceruloplasmin examination. At the age of 55 he died of pneumonia. Post-mortem examination revealed minimal non-specific neuropathological features for HD (Vonsattel's grade 0), that is, no visible fibrillary gliosis in the striatum, and few neuronal loss and only proliferation of astrocytes (astrocytosis) in the striatum. Molecular-genetic study the patient's brain tissues and his youngest son's blood was performed. These studies revealed 40 CAG repeats in the patient, 56 CAG repeats in his youngest son. These results suggest they may be HD. Vonsattel et al. [ 1998] insist that grade 0 comprises 1% of all HD brains, and grade 1 comprises 4% of all HD brains. But we could not find any reports in which the clinical and neuropathological features were described in detail on the cases with clinically and molecular genetically diagnosed HD without specific pathological findings. Therefore, we present in detail the clinical and neuropathological features of such case.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749290

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  7 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 2.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

3.  Genetic modifiers of Drosophila palmitoyl-protein thioesterase 1-induced degeneration.

Authors:  Haley Buff; Alexis C Smith; Christopher A Korey
Journal:  Genetics       Date:  2007-04-03       Impact factor: 4.562

4.  Clinical severity of Huntington's disease does not always correlate with neuropathologic stage.

Authors:  Jagan A Pillai; Lawrence A Hansen; Eliezer Masliah; Jody L Goldstein; Steven D Edland; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2012-06-01       Impact factor: 10.338

5.  Persistence of intact retinal ganglion cell terminals after axonal transport loss in the DBA/2J mouse model of glaucoma.

Authors:  Matthew A Smith; Christina Z Xia; Christine M Dengler-Crish; Kelly M Fening; Denise M Inman; Brett R Schofield; Samuel D Crish
Journal:  J Comp Neurol       Date:  2016-05-03       Impact factor: 3.215

6.  Metabolic and transcriptomic analysis of Huntington's disease model reveal changes in intracellular glucose levels and related genes.

Authors:  Gepoliano Chaves; Rıfat Emrah Özel; Namrata V Rao; Hana Hadiprodjo; Yvonne Da Costa; Zachary Tokuno; Nader Pourmand
Journal:  Heliyon       Date:  2017-08-30

7.  Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's Disease.

Authors:  Zhuowei Du; Margot Tertrais; Gilles Courtand; Thierry Leste-Lasserre; Laura Cardoit; Frédérique Masmejean; Christophe Halgand; Yoon H Cho; Maurice Garret
Journal:  Front Mol Neurosci       Date:  2017-06-20       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.